BetterScholar BetterScholar
11
Role
Title
Level Year L/R
🐜 Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial
12 auth. M. Simons, B. Annex, R. Laham, N. Kleiman, T. Henry, H. Dauerman, ... J. Udelson, E. Gervino, M. Pike, M. J. Whitehouse, Thomas Moon, N. Chronos
9 2002
9
🐜
🐜 Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
16 auth. P. Gill, J. Wernz, D. Scadden, P. Cohen, G. Mukwaya, J. V. Von Roenn, M. Jacobs, S. Kempin, I. Silverberg, G. Gonzales, ... M. Rarick, A. Myers, F. Shepherd, C. Sawka, M. Pike, M. E. Ross
8 1996
8
🐜
🐜 Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
27 auth. R. Hirschberg, J. Kopple, P. Lipsett, E. Benjamin, J. Minei, T. Albertson, Mark A. Munger, Michael Metzler, G. Zaloga, M. Murray, S. Lowry, J. Conger, W. Mckeown, M. O'Shea, R. Baughman, ... K. Wood, M. Haupt, Roger A. Kaiser, H. Simms, D. Warnock, W. Summer, R. Hintz, B. Myers, Kathrine Haenftling, W. Capra, M. Pike, H. Guler
8 1999
8
🐜
🐜 Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study.
10 auth. R. Laham, N. Chronos, M. Pike, M. Leimbach, J. Udelson, J. Pearlman, ... R. Pettigrew, M. J. Whitehouse, C. Yoshizawa, M. Simons
7 2000
7
🐜
🐜 Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
295 auth. M. Clowse, D. Wallace, R. Furie, M. Petri, M. Pike, P. Leszczyński, C. Neuwelt, K. Hobbs, M. Keiserman, L. Duca, K. Kalunian, C. Gălăţeanu, S. Bongardt, C. Stach, C. Beaudot, ... B. Kilgallen, C. Gordon, A. Batalov, M. Bojincă, R. Djerassi, L. Duca, P. Horák, Z. Kolarov, R. Milasiene, D. Monova, K. Otsa, M. Pileckytė, T. Popova, F. Radulescu, R. Rashkov, S. Rednic, M. Repin, R. Stoilov, D. Tegzová, N. Vezikova, P. Vítek, C. Zainea, Far East, H. Baek, Y. Chen, Y. Chiu, C. Cho, C. Chou, J. Choe, C. Huang, Y. Kang, S. Kang, N. Lai, S. Lee, W. Park, S. Shim, C. Suh, W. Yoo, H. Á. Armengol, F. A. Zapata, M. Santiago, F. Cavalcanti, W. Chahade, L. Costallat, M. Keiserman, J. Alcala, C. Remus, L. Roimicher, M. Abu-Shakra, V. Agarwal, N. Agmon-Levin, J. Kadel, Y. Levy, D. Mevorach, D. Paran, T. Reitblat, I. Rosner, V. Shobha, Z. Sthoeger, D. Zisman, K. Ayesu, S. Berney, J. Box, H. Busch, J. Buyon, J. Carter, J. Chi, M. Clowse, R. Collins, K. Dao, I. Diab, A. Dikranian, M. El-Shahawy, N. Gaylis, J. Grossman, E. Halpert, J. Huff, W. Jarjour, A. Kao, R. Katz, A. Kennedy, M. Khan, A. Kivitz, M. Kohen, T. Lawrence–Ford, J. Lawson, M. Levesque, M. Lowenstein, A. Majjhoo, R. Mcarthur, D. Mclain, J. Merrill, A. Murillo, S. Neucks, G. Niemer, G. Noaiseh, C. Parker, C. Pantojas, D. Pattanaik, M. Petri, P. Pickrell, J. Reveille, A. Roman-Miranda, N. Rothfield, A. Sankoorikal, M. Sayers, A. Singhal, A. Snyder, C. Striebich, Q. Vo, J. V. Von Feldt, D. Wallace, M. Wasko, C. Young, S. Adelstein, S. Hall, G. Littlejohn, D. Nicholls, M. Suranyi, Z. Amoura, B. Bannert, F. Behrens, Lada Perez, K. Chakravarty, F. D. Gonzales, K. Davies, A. Doria, P. Emery, A. Fernández-Nebro, M. Govoni, E. Hachulla, B. Hellmich, F. Houssiau, M. Malaise, J. Margaux, Y. Maugars, S. Muñoz-Fernández, F. Navarro, J. Ordi‐Ros, R. Pellerito, J. Peña-Sagredo, E. Roussou, R. Schmidt, E. Úcar-Angulo, J. Viallard, R. Westhovens, M. Worm, C. Yee, S. Nayiager, H. Reuter, C. Spargo, B. Bazela, M. Brzosko, D. Chudzik, B. Gasztonyi, P. Géher, R. Ionescu, S. Jeka, L. Kemény, E. Kiss, P. Kotyla, L. Kovács, V. Kovalenko, E. Kucharz, B. Kwiatkowska, P. Leszczyński, E. Levchenko, G. Lysenko, M. Majdan, C. Mihailov, S. Nalotov, M. Nedelciu, M. Pavel, T. Raskina, B. Rebrov, E. Rezuș, T. Semen, S. Smakotina, M. Stanislavchuk, M. Stanislav, I. Szombati, G. Szűcs, G. Udrea, J. Zajdel, A. Zoń-Giebel, R. Bonfiglioli, R. Bustamante, E. Klumb, G. Ramírez, C. Neiva, M. Olguin, J.Reyes Gonzaga, A. Scotton, S. Ayala, A. Ximenes, R. Sharma, C. Srikantiah, J. Aelion, C. Aranow, M. Baker, A. Chadha, J. Chao, W. Chatham, A. Chow, C. Clay, S. Cohen‐Gadol, D. Conaway, J. Denburg, A. Escalante, L. Espinoza, J. Fiechtner, I. Fortin, A. Fraser, R. Furie, D. Gladman, D. Goddard, M. Goldberg, R. González-Rivera, J. Gorman, R. Griffin, D. Haaland, D. Halter, A. Hemaiden, K. Hobbs, V. Joshi, S. Lim, K. Kalunian, G. Karpouzas, M. Khraishi, R. Lafyatis, R. Lidman, C. Lue, M. Mohan, P. Mease, C. Mehta, W. Mizutani, A. Nami, J. Nascimento, C. Neuwelt, J. Pappas, J. Pope, A. Porges, G. Roane, D. Rosenberg, S. Ross, C. Saadeh, C. Scoville, Y. Sherrer, M. Solomon, W. Surbeck, G. Valenzuela, P. Waller, R. Alten, C. Baerwald, B. Bienvenu, S. Bombardieri, J. Braun, L. Dival, G. Espinosa, I. F. Fernández, J. Gómez-Reino, C. Gordon, F. Hiepe, N. Hopkinson, D. Isenberg, A. Jacobi, C. Jorgensen, V. Guern, C. Paul, J. Pego-Reigosa, J. R. Heredia, A. Rubbert-Roth, M. Sabbadini, J. Schroeder, A. Schwarting, W. Spieler, G. Valesini, J. Wollenhaupt, A. Z. Mendoza, C. Zouboulis
7 2016
7
🐜
🐬 Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis
D. Hunter, M. Pike, B. Jonas, E. Kissin, J. Krop, T. McAlindon
7 2010
7
🐬
🐜 Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
13 auth. Eric F Morand, M. Pike, J. Merrill, R. V. van Vollenhoven, V. Werth, C. Hobar, N. Delev, V. Shah, B. Sharkey, T. Wegman, ... I. Catlett, Subhashish Banerjee, S. Singhal
6 2022
6
🐜
🐜 Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease
9 auth. M. Bush, E. Samara, M. J. Whitehouse, C. Yoshizawa, D. Novicki, M. Pike, ... R. Laham, M. Simons, N. Chronos
5 2001
5
🐜
🐜 Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study
19 auth. D. Wallace, K. Hobbs, M. Clowse, M. Petri, V. Strand, M. Pike, J. Merrill, P. Leszczyński, C. Neuwelt, S. Jeka, ... F. Houssiau, M. Keiserman, J. Ordi‐Ros, S. Bongardt, B. Kilgallen, C. Gălăţeanu, K. Kalunian, R. Furie, C. Gordon
5 2016
5
🐜
🐜 Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma
13 auth. J. Nemunaitis, T. Fong, J. Robbins, G. Edelman, W. Edwards, R. S. Paulson, J. Bruce, N. Ognoskie, D. Wynne, M. Pike, ... K. Kowal, J. Merritt, D. Ando
5 1999
5
🐜
🐜 LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
13 auth. E. Morand, M. Pike, J. Merrill, R. van Vollenhoven, V. Werth, C. Hobar, N. Delev, V. Shah, B. Sharkey, T. Wegman, ... I. Catlett, S. Banerjee, S. Singhal
3 2022
3
🐜